Daxor (DXR) Earns Buy Rating from Analysts at Ascendiant Capital Markets

Ascendiant Capital Markets assumed coverage on shares of Daxor (NYSEAMERICAN:DXR) in a research note released on Thursday, BenzingaRatingsTable reports. The firm issued a buy rating and a $20.00 price objective on the stock.

NYSEAMERICAN:DXR opened at $9.66 on Thursday. Daxor has a 1-year low of $4.30 and a 1-year high of $19.95.

An institutional investor recently bought a new position in Daxor stock. Shine Investment Advisory Services Inc. purchased a new stake in Daxor Co. (NYSEAMERICAN:DXR) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 45,454 shares of the company’s stock, valued at approximately $512,000. Shine Investment Advisory Services Inc. owned 1.22% of Daxor as of its most recent SEC filing.

Daxor Company Profile

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.

Featured Story: Recession

Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.